% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koelsche:127149,
      author       = {C. Koelsche$^*$ and L. Schweizer$^*$ and M. Renner and A.
                      Warth and D. Jones$^*$ and F. Sahm$^*$ and D. E. Reuss$^*$
                      and D. Capper$^*$ and T. Knösel and B. Schulz and I.
                      Petersen and A. Ulrich and E. K. Renker and B. Lehner and S.
                      Pfister$^*$ and P. Schirmacher and A. von Deimling$^*$ and
                      G. Mechtersheimer},
      title        = {{N}uclear relocation of {STAT}6 reliably predicts
                      {NAB}2-{STAT}6 fusion for the diagnosis of solitary fibrous
                      tumour.},
      journal      = {Histopathology},
      volume       = {65},
      number       = {5},
      issn         = {0309-0167},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2017-03175},
      pages        = {613 - 622},
      year         = {2014},
      abstract     = {Nuclear relocation of STAT6 has been shown in tumours with
                      NAB2-STAT6 fusion, and has been proposed as an ancillary
                      marker for the diagnosis of solitary fibrous tumours (SFTs).
                      The aim of this study was to verify the utility of STAT6
                      immunohistology in diagnosing SFT.A total of 689
                      formalin-fixed paraffin-embedded tumours comprising 35
                      pleural SFTs and 654 other mesenchymal tumours were
                      investigated for STAT6 expression using
                      immunohistochemistry. Nine dedifferentiated liposarcomas
                      (DDLSs) and five SFTs were also examined for the presence of
                      NAB2-STAT6 fusion at the protein level using the proximity
                      ligation assay (PLA), and for copy number variants (CNVs)
                      with the Illumina Infinium Human Methylation450 array.
                      Thirty-four of 35 SFTs showed strong nuclear STAT6
                      expression. Furthermore, five of 68 DDLSs, two of 130
                      undifferentiated pleomorphic sarcomas and one of 63 cases of
                      nodular fasciitis showed moderate to strong nuclear STAT6
                      expression. The PLA indicated the presence of NAB2-STAT6
                      fusion protein in SFTs, but signal was also detected in some
                      DDLSs. Copy number analysis showed an overall low frequency
                      of chromosomal imbalances in SFTs, but complex karyotypes in
                      DDLSs, including amplification of STAT6 and MDM2 loci.The
                      detection of nuclear relocation of STAT6 with
                      immunohistochemistry is a characteristic of SFTs, and may
                      serve as a diagnostic marker that indicates NAB2-STAT6
                      fusion and helps to discriminate SFTs from histological
                      mimics.},
      keywords     = {Biomarkers, Tumor (NLM Chemicals) / NAB2 protein, human
                      (NLM Chemicals) / Repressor Proteins (NLM Chemicals) / STAT6
                      Transcription Factor (NLM Chemicals) / STAT6 protein, human
                      (NLM Chemicals)},
      cin          = {G380 / B062},
      ddc          = {610},
      cid          = {I:(DE-He78)G380-20160331 / I:(DE-He78)B062-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24702701},
      doi          = {10.1111/his.12431},
      url          = {https://inrepo02.dkfz.de/record/127149},
}